validated Platform.
large Market.
Early Entry point.
Metacell sits at the intersection of two megatrends: the global push to secure pharmaceutical supply chains, and the rise of synthetic biology as an industrial platform. We’ve built the technical foundation. Now we’re scaling it.
Why Now?
Two ways
The Market
The global fermentation-derived API market is large, established, and worth billions annually. Yet most manufacturers are leaving margin on the table — yields are suboptimal, strain development is slow, and the economics of complex API production remain unnecessarily tight. Metacell targets that gap directly.
The Moat
Screening millions of mutants at speed, in filamentous systems, for complex APIs — that’s not something a competitor builds in a year. It requires deep biological expertise, proprietary workflows, and a platform validated through years of development. We have it. They don’t.
